Clinical Trial Update: The Bioequivalence Of Two Different Lurasidone Formulations In Patients [Phase 1]

View source ↗

Summary

Phase 1 study comparing the bioavailability of two lurasidone formulations in patients with schizophrenia to determine equivalence.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Latuda (lurasidone)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED